Vanguard Group’s ACELYRIN SLRN Stock Holding History

Vanguard Group’s Portfolio SLRN Stock Details SLRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-4,079,706	Closed	-$10.1M	–	4323
2025 Q1	$10.1M	Sell	4,079,706 -304	-0%	-$723	﹤0.01%	2842
2024 Q4	$12.8M	Buy	4,080,010 +13,021	+0.3%	+$63K	﹤0.01%	2816
2024 Q3	$20.1M	Sell	4,066,989 -676,412	-14%	-$3.49M	﹤0.01%	2588
2024 Q2	$20.9M	Sell	4,743,401 -1,494,142	-24%	-$7M	﹤0.01%	2546
2024 Q1	$42.1M	Buy	6,237,543 +81,633	+1%	+$620K	﹤0.01%	2241
2023 Q4	$45.9M	Buy	6,155,910 +2,966,883	+93%	+$25.3M	﹤0.01%	2226
2023 Q3	$32.4M	Buy	3,189,027 +116,847	+4%	+$2.48M	﹤0.01%	2337
2023 Q2	$64.2M	Buy	+3,072,180	New	+$62.8M	﹤0.01%	2080

Other funds holding SLRN

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Vanguard Group's SLRN Position: Q2 2025 in Review

Vanguard Group sold out of ACELYRIN (SLRN) in Q2 2025, closing a stake of 4,079,706 shares — an estimated $10.1M sold.

Vanguard Group first reported a position in SLRN in Q2 2023 and held it in 8 quarters. The position peaked at $64.2M in Q2 2023. 2 funds tracked by Wall St. Rank hold SLRN as of Q2 2025.

Vanguard Group reported no remaining ACELYRIN position as of Q2 2025 after selling out during the quarter.
Vanguard Group sold 4,079,706 ACELYRIN shares in Q2 2025, an estimated $10.1M.
Vanguard Group first reported a position in ACELYRIN in Q2 2023 and held it in 8 quarters.
Vanguard Group's ACELYRIN position peaked at $64.2M in Q2 2023.
2 funds tracked by Wall St. Rank held ACELYRIN as of Q2 2025.

Based on Vanguard Group's 13F filing for Q2 2025, filed 11 Aug 2025.